FDA approves Eli Lilly's treatment which slows symptoms down

The US has approved donanemab, a treatment for disease that helps the body remove the hallmark plaque that builds up in the brain and causes dementia.

Made by Indianapolis-based Eli Lilly, donanemab is a monoclonal antibody treatment designed to slow the progression of .

Now approved, Eli Lilly said it will be sold under the name Kisunla and will cost $695 per vial - amounting to about $32,000 a year. The drug is administered by once-monthly infusions.

Load More